Syndax says revumenib plus intensive chemo posts 97% remission rate in Phase 1 newly diagnosed AML trial at EHA 2026

Syndax

Syndax

SNDX

0.00
  • Syndax highlighted new Revuforj (revumenib) data presented at EHA 2026, spanning real-world use, frontline combinations, post-transplant maintenance, and additional leukemia subtypes.
  • Across studies, revumenib produced high response rates in NPM1-mutated or KMT2A-rearranged acute leukemia, including deep remissions when combined with standard regimens.
  • Post-transplant use in a trial analysis showed strong survival outcomes, supporting a potential maintenance strategy to extend remission durability.
  • Data in NUP98-rearranged acute leukemia showed meaningful activity in a hard-to-treat population, expanding the drug’s commercial and clinical reach beyond its current core segments.
  • Safety findings were broadly consistent with the established profile, with no new signals highlighted in the EHA presentations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110703PRIMZONEFULLFEED9745489) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.